BHVN (Biohaven) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biohaven 3-Year Revenue Growth Rate?

Biohaven's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Biohaven's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Biohaven's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biohaven's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biohaven's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Biohaven's 3-Year Revenue Growth Rate falls into.

Biohaven 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Biohaven (NYSE:BHVN) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Biohaven 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Biohaven's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

215 Church Street, New Haven, CT, USA, 06510

Website

https://www.biohavenpharma.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Executives

John W Childs	director	111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric	director, officer: Chief Executive Officer	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Bruce Car	officer: Chief Scientific Officer	AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Irina Antonijevic	director	215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten	officer: Chief Financial Officer	215 CHURCH STREET, NEW HAVEN CT 06510
George C. Clark	officer: VP, Chief Accounting Officer	215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory	director	8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin	director	C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile	officer: SVP, Clinical Operations	C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta	director	540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd.	10 percent owner	215 CHURCH STREET, NEW HAVEN CT 06510